"Pharmaceutical Express" AZ Dagli net new adaptation was approved Lilly Q3 global revenue of $5.741 billion

October 28, 2020 / Pharmaceutical Information At a Glance: Pfizer's oral JAK1 inhibitors are eligible for FDA priority review; NMPA approves AstraZenega's net new adaptation; Jiahe Bio submits an application for the listing of Invlich mono-biosimilars; Lilly Q3's global total revenue of $5,741 million; and the resignation of the Chairman of North China Pharmaceuticals... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Drug Review approval 16 items of information or will be made public October 27, CDE issued the "Drug Review and Approval Information Disclosure Management Measures (Draft for Comments)", respectively, set out the purpose and basis for development, as well as the drug review center and the basic requirements of the applicant, etc. ;
(CDE official website) 33 kinds of banned pesticide testing equipment can be shared within the Group October 27, Yunnan Provincial Drug Administration issued a notice on further strengthening the quality management of drug production.
In view of the "Chinese Pharmacopoeia" (2020 edition) of Chinese herbal medicine, Chinese medicine drink tablets testing general rules added 33 kinds of banned pesticide testing equipment is expensive, by the production enterprises to equip their own equipment for inspection is more difficult situation.
from December 30, 2020, during a certain transition period, the production enterprises may share inspection resources within the Group for inspection or entrust third-party testing institutions with statutory inspection and testing qualifications for inspection.
(Yunnan Provincial Drug Administration) Zhejiang Province, the implementation date of the third batch of national procurement to determine Zhejiang Province on October 27 issued "on the third batch of centralized procurement of drugs organized by the state organization (Zhejiang) in the online procurement of drugs", the content shows that the third batch of National Mining Zhejiang selected results will be officially implemented on November 10, 2020, October 28, the selection of products will be listed in Zhejiang Province drug procurement platform.
(Zhejiang Pharmaceutical Procurement Center) Henan Province supplies procurement results released on October 26, Henan Province Public Resources Trading Center issued "on the public announcement of Henan Province medical supplies centralized belt procurement results of the proposed selection of the notice", artificial crystals and retaining needles medical supplies to be selected results of the public, will be 95520 artificial crystals and 12351382 retention needles for belt procurement.
(Henan Province Public Resources Trading Center) to open a pharmacy with only one license since this year, Xi'an City Market Bureau formulated and issued "on the exploration and development of drug retail industry "one industry, one certificate" reform pilot work", taking the lead in the stone forest area, the international port area to carry out drug retail industry "one industry one certificate" reform pilot work.
a pharmacy, only one comprehensive license, drug business license, the second type of medical device business record certificate, the third type of medical device business license, food business license, etc. are not used.
2 (Xi'an Market Bureau) Part 2 watched Pfizer announce third-quarter financial cuts October 27 Pfizer announced third-quarter financial cuts.
The first phase of the phase 1 phase of clinical research assets in the study of NASH drugs PF-05221304, the second phase of the phase obsolete assets for arthritis candidate drugs PF-06650833, in addition, is in phase 1 clinical study of the prostate cancer treatment vaccine PF-06753512 has also been shelved.
(Sina Pharmaceutical News) Lilly's third-quarter global revenue of $5,741 million on October 27, Lilly released its third-quarter report.
third quarter, Lilly's global revenue was $5,741 million, up 5 percent from a year earlier, according to a report.
's key growth products since 2014: Taltz, Ingley Net, Remo Reed Mono-Resistance and other contributing revenue growth of nearly 9 percent, accounting for about 52 percent of total revenue for the quarter.
(Sina Pharmaceutical News) Novarma Q3 China results increased 13% October 27, Novarma released its first three quarters of 2020 results, net sales revenue of $35.889 billion, up 4% YoY;
, China's revenue of $667 million, or 13 percent, was driven by double-digit growth rates in Cosentyx and Entresto.com.
(Pharmaceutical Rubik's Cube Info) Beda Pharmaceuticals' third-quarter net profit increased 21.20% YoY today, Bayda Pharmaceuticals released its third-quarter results. the
report showed that Beda Q3's single-quarter revenue was RMB556 million, up 15.45% YoY;
Database (Insight Database) Frontier Bio is officially listed on the Science and Technology Board today, and Frontier Bio is listed on the Science and Technology Board on the Shanghai Stock Exchange.
the company's issue price of Rmb20.5 per share, with a net capital raising of Rmb1,717m, according to the company's results.
currently, Frontier Biology has a new drug on the market, two new drugs in the research phase of clinical trials.
(Pharmaceutical Mingkangde) Furen Pharmaceuticals financial fraud was fined 5.9 million yuan Real controller Zhu Wenchen 10 years market ban October 27, Furen Pharmaceuticals announced to the public, the company received the CSRC issued the "Administrative Penalty Decision" and "Market Ban Decision."
documents show that Furen Pharmaceuticals' performance has been false for years, and the company and related personnel have been fined a total of 5.9 million yuan.
, zhu Wenchen, the company's real controller, has been banned from the securities market for 10 years.
(Sina Pharmaceutical News) Xindili single anti-third quarter sales broke 600 million October 27, Xinda Bio issued a notice to disclose Daboshu (Xindili single anti-injection) Q3 sales in 2020.
sales exceeded 600 million in the third quarter and are expected to exceed 2 billion by 2020, according to a statement from the company.
,26, North China Pharmaceuticals announced that its board of directors received a written resignation report from Yang Guoc, the company's chairman, on October 26, 2020.
(Seber Blue) China-U.S. East China 2020Q3 revenue of 2.726 billion yuan October 26, East China Pharmaceuticals announced the first three quarters of 2020 results.
's core subsidiary, China-East China, achieved operating income of RMB8.810 billion, up 5.01% YoY, and net profit of RMB1,939 million, up 4.68% YoY.
(Pharmaceutical Rubik's Cube Info) a number of armored enterprises product recall October 26, according to the State Drug Administration's official website released the news, Philips Medical (Suzhou) Co., Ltd. on the mobile digital medical X-ray photography system actively recalled, the recall level of three, involving 22 units in China.
, Cherry Blossom Medical Technology (Taizhou) Co., Ltd. has voluntarily recalled frozen slicers at a level of 2, involving 109 units in China.
(State Drug Administration) Gree production of medical equipment on October 26, Tianjin Gree Xinyu Medical Equipment Co., Ltd. was established, registered capital of 50 million yuan, the legal representative is Dong Mingzhu, the company by Zhuhai Gree Electric Co., Ltd. 100% of the shares.
(Seber Blue Devices) East China Pharmaceuticals acquired a 20% stake in swiss boric acid company recently, East China Pharmaceuticals announced that its wholly-owned subsidiary, Sinclair OF, has invested 6 million euros to acquire a 20% stake in Kylane.
Sinclair will have the right to obtain the IP (intellectual property) and global interests of Kylane's two key research and development products in the area of facial and body fillers at an agreed price.
Sciences joined forces with Thrive to promote blood cancer testing today, exact Sciences and Thrive Earlier Detection jointly announced that they had reached an agreement to acquire Trive.
acquisition will combine CancerSEEK, Trive's early screening test, with Act Sciences' scientific platform, clinical organization and business infrastructure to build a leading blood-based multi-cancer screening company.
(Pharmaceuticals) Precision Oncology Treatment 2.0 founded and financed more than $100 million recently, Scorpion Therapeutics announced the creation of the company and completed a $108 million financing, Atlas Venture, Omega Funds and Vida Ventures led the round of financing, abingworth and Partners HealthCare Innovation also participated in this round of financing.
Pfizer's oral JAK1 inhibitor has been approved for FDA Priority Review Pfizer announced today that the FDA has accepted the company's application for abrocitinib's new drug and granted it priority review eligibility.
Abrocitinib is a daily oral JAK1 inhibitor used to treat patients with moderate to severe endexual dermatitis over 12 years of age.
(Pharmaceutical Mingkang) NMPA approved AstraZeneta's net new adaptation today, AstraZenecom announced that the National Drug Administration approved the renewal of AstraZeneta Down ® (generic name: Dagrid Net) China manual, incorporating some of the data from the results of the DECLARE-TIMI 58 3 clinical study.
compared to placebos, Dagrid was able to effectively reduce the risk of hospitalization or cardiovascular death from heart failure in adults with type 2 diabetes who had been diagnosed with cardiovascular disease or multiple cardiovascular risk factors.
(immediate drug news) Hengrui pharmaceutical injection with HR17020 to start clinical October 27, Insight database shows that Hengrui 2 classes of modified new drug "injection HR17020" for the first time started clinical, its indication is to prevent renal syndrome patients venous thromboembolism.
(Insight Database) Jia and Bio filed an application for the listing of Invlich monobiotics on October 27, Jia and Bio announced that it had submitted to the NMPA a listing application for the Invlich monobiotics GB242, the second listing application submitted by Jia and Bio following the PD-1 antibody Jeno monosanti.
addition to Johnson and Johnson's original research drug queer (Invlisi mono-resistance), there is currently no Invlisi monobial similar drugs approved for market in China.
(Pharmaceutical Mission) Stone Pharmaceutical Group 2 heavy-weight varieties over-evaluation October 26, the State Drug Administration's official website shows that Stone Pharmaceutical Group's Nofluorosa star tablets, cephalosporading capsules through a consistent evaluation.
2019, sales of nofluorosa star and cephalospora ding in China's public medical institutions will be 130 million yuan and 370 million yuan, respectively, according to data from china's 100 million meters intranet.
to date, a total of 34 varieties of Stone Pharmaceutical Group have passed/treated with consistency evaluation.
(Mi net) Yuandong biological anti-dementia drug first imitation will take the State Drug Administration official website shows that Chengdu Yuandong biological imitation of 3 types of reported hydrochloric acid methionine slow release capsule into the administrative approval stage, is expected to take the first imitation.
addition to the hydrochloric acid methion slow release capsule, Chengdu Yuandong Bio's Capeta bin tablets, Glon ammonium bromide injection registration status has also been changed to "in the approval."
(Mienet)